On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compounds at Two Upcoming Events

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will be presenting at the first ever Targeting Innate Immunity Congress. Dr. Tesi and Dr. … Continue reading “QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Executives to Speak, Showcase Innate Compounds at Two Upcoming Events”

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR … Continue reading “QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer”

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, recently reported financial results for the second quarter ended June 30, 2019 (http://ibn.fm/shHin). An article discussing the company reads, “Apart from announcing strategic developments, INmune Bio also presented its most important financial results for … Continue reading “QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results”

QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03

INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://ibn.fm/m1Iy3). An article discussing the company reads, “‘The goal of the Phase I study is to … Continue reading “QualityStocksNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03”

INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment

The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Announces Continuous Advancement of Clinical Program, New Strategic Appointment”

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its financial results for the second quarter ended June 30, 2019 and also provided a year-to-date business update. “This year we remained focused on advancing our pipeline,” INmune Bio CEO RJ … Continue reading “QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Releases Q2 2019 Financial Results, Provides Shareholder Update”

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Member

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Edgardo “Ed” Baracchini, Ph.D., has joined its board of directors. Per the update, Dr. Baracchini’s impressive biotech business development background includes more than 25 years of experience in structuring and negotiating … Continue reading “QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Member”

INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients

INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment The annual immuno-oncology summit brings together leaders from across the immunotherapy … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients”

QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s Seventh Annual Immuno-Oncology Summit in Boston. Per the update, the company’s INB03 is being developed as part of combination immunotherapy to … Continue reading “QualityStocksNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Reports Positive Preliminary Data from Phase I Clinical Trial of INB03”

INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology

INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions The congress was a paramount event in the field of immunotherapy, allowing … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered